Board/Management Information • Jan 6, 2022
Board/Management Information
Open in ViewerOpens in native device viewer
BERGENBIO APPOINTS ANDERS TULLGREN AS CHAIRMAN OF BOARD
Bergen, Norway, 6 January 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective AXL kinase inhibitors for
severe unmet medical need, announces today the appointment of Anders Tullgren to
succeed Sveinung Hole as Chairman of the Board of Directors, effective today.
Sveinung Hole has been Chairman of the Board since March 2019 and will continue
to serve as a Board Member.
Anders Tullgren has over 35 years of global experience in both large
pharmaceutical and small/mid-size biotech environments, with senior leadership
roles in the United States, Germany, France, the United Kingdom, and the Nordic
region. He spent over 20 years at Bristol Myers Squibb, most recently as
President, Intercontinental Region at the firm, with responsibility across 30
countries, 5,000 employees and a turnover of over 2.7 billion USD. Anders has in
his career worked with several oncology products and was leading the successful
launch of BMS immuno-oncology portfolio in the intercontinental region.
Anders is an experienced non-executive director with current Board and Chair
positions at Branding Science Ltd (UK), Xbrane Biopharma AB (Sweden), Farmalisto
(Panama) and Dizlin Pharmaceuticals AB (Sweden). He holds an MSc in
Pharmaceutical Studies from Uppsala University (Sweden) and a Diploma in
Marketing & Business Administration from MIS (Sweden).
Martin Olin, Chief Executive Officer of BerGenBio, commented: "We're delighted
to welcome Anders Tullgren as Chairman. Anders' experience and deep knowledge of
development, commercialization and growth planning is highly valuable in our
journey to provide novel therapeutic modalities to treat severe diseases. I'd
like to take this opportunity to thank Sveinung for his excellent leadership of
the Board during the past few years, which have seen a number of important
milestones as we progress our clinical trials."
On his appointment as Chairman of the Board, Anders Tullgren said: "It is an
honor to have the opportunity to take on the role of Chairman and to work within
an incredible company and alongside a strong leadership team. I look forward to
supporting BerGenBio as it advances the progression of its lead candidate,
bemcentinib, and working closely with Martin, Sveinung and the rest of the
Board."
-End-
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II clinical development
programme focused on combination and single agent therapy in cancer and COVID
-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is
undergoing phase I clinical testing. In parallel, BerGenBio is developing a
potential companion diagnostic test to identify patient populations most likely
to benefit from AXL inhibition: this is expected to facilitate more efficient
registration trials supporting a precision medicine-based commercialisation
strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit? www.bergenbio.com
Contacts
Martin Olin CEO, BerGenBio ASA
Rune Skeie, CFO, BerGenBio ASA
International Media Relations
Mary-Jane Elliott, Chris Welsh, Lucy Featherstone
Consilium Strategic Communications
+44 20 3709 5700
Forward looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.